GlycoMimetics Inc. Daily Stock Analysis

Daily Stock Analysis, GLYC, GlycoMimetics Inc, priceseries

GlycoMimetics Inc. Daily Stock Analysis
Stock Information
Open
1.10
Close
1.05
High
1.10
Low
1.03
Previous Close
1.07
Daily Price Gain
-0.02
YTD High
1.61
YTD High Date
Jan 4, 2022
YTD Low
1.01
YTD Low Date
Jan 24, 2022
YTD Price Change
-0.53
YTD Gain
-33.54%
52 Week High
3.62
52 Week High Date
Mar 18, 2021
52 Week Low
1.01
52 Week Low Date
Jan 24, 2022
52 Week Price Change
-1.90
52 Week Gain
-64.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 12. 2017
5.00
Jun 5. 2017
11.16
15 Trading Days
123.12%
Link
LONG
Sep 15. 2017
11.82
Oct 2. 2017
13.45
11 Trading Days
13.77%
Link
LONG
Nov 17. 2017
12.27
Dec 20. 2017
15.73
22 Trading Days
28.18%
Link
LONG
Dec 21. 2017
16.14
Jan 16. 2018
18.59
15 Trading Days
15.20%
Link
LONG
Jan 17. 2018
19.65
Feb 1. 2018
22.36
11 Trading Days
13.77%
Link
LONG
Dec 31. 2018
9.47
Jan 14. 2019
10.41
9 Trading Days
9.94%
Link
LONG
Sep 6. 2019
3.48
Sep 24. 2019
4.37
12 Trading Days
25.61%
Link
LONG
Oct 10. 2019
4.37
Nov 7. 2019
5.31
20 Trading Days
21.50%
Link
LONG
Jun 26. 2020
3.46
Jul 24. 2020
4.53
19 Trading Days
30.89%
Link
LONG
Oct 5. 2020
3.27
Oct 14. 2020
3.45
7 Trading Days
5.61%
Link
LONG
Nov 9. 2020
3.12
Nov 20. 2020
3.67
9 Trading Days
17.48%
Link
LONG
Aug 25. 2021
1.99
Sep 14. 2021
2.16
13 Trading Days
8.70%
Link
LONG
Feb 24. 2022
1.12
Mar 3. 2022
1.18
5 Trading Days
5.36%
Link
Company Information
Stock Symbol
GLYC
Exchange
NasdaqGM
Company URL
http://www.glycomimetics.com
Company Phone
240-243-1201
CEO
Rachel K. King
Headquarters
Maryland
Business Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD 20850
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001253689
About

GlycoMimetics, Inc. operates as a clinical stage biotechnology company, which focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease-related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani in April 2003 and is headquartered in Rockville, MD.

Description

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors. The company has a collaborative research and development agreement with Pfizer Inc. GlycoMimetics, Inc. was founded in 2003 and is headquartered in Rockville, Maryland.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading